title: Plasma pentraxin3 and arterial stiffness in men with obstructive sleep apnea.
abstract: BACKGROUND
  Obstructive sleep apnea (OSA) induces inflammation and vascular damage that might contribute to an increased risk of cardiovascular disease (CVD). However, the mechanisms linking OSA and CVD are not fully understood. Pentraxin3 may play a significant role in vascular inflammation and damage. Currently, there is lack of data on pentraxin3 and its role in vascular damage associated with OSA.
  
  
  METHODS
  We enrolled 50 males with OSA and 25 controls matched for age and body mass index (BMI). Patients with OSA were further divided into mild and moderate to severe groups. We measured plasma pentraxin3 and evaluated vascular damage using an arterial stiffness parameter--the cardio-ankle vascular index (CAVI)--in all subjects. In the moderate to severe OSA group, pentraxin3 and CAVI were repeatedly measured following continuous positive airway pressure (CPAP) therapy for 1 month.
  
  
  RESULTS
  Pentraxin3 levels in the moderate-to-severe OSA group were significantly higher than those in the mild OSA and control groups, with median levels (25th-75th percentile) of 2.36 (1.79-2.78), 1.63 (1.15-2.05), and 1.53 (1.14-2.04) ng/ml, respectively (P < 0.01). Pentraxin3 level was independently correlated with CAVI (coefficient, 0.34 P < 0.01). In the moderate-to-severe OSA group, pentraxin3 and CAVI levels were significantly reduced (P < 0.01 and P = 0.04, respectively) after 1 month of CPAP therapy.
  
  
  CONCLUSIONS
  Plasma pentraxin3 and arterial stiffness levels in the moderate-to-severe OSA group were greater than the corresponding levels in patients without OSA. However, pentraxin3 level can be managed by CPAP therapy for OSA.
authors.affiliation: Sleep Center, Toranomon Hospital, Tokyo, Japan. kasai-t@mx6.nisiq.net
authors.forename: Takatoshi
authors.initials: T
authors.lastname: Kasai
authors.forename: Kenji
authors.initials: K
authors.lastname: Inoue
authors.forename: Takiko
authors.initials: T
authors.lastname: Kumagai
authors.forename: Mitsue
authors.initials: M
authors.lastname: Kato
authors.forename: Fusae
authors.initials: F
authors.lastname: Kawana
authors.forename: Mina
authors.initials: M
authors.lastname: Sagara
authors.forename: Sugao
authors.initials: S
authors.lastname: Ishiwata
authors.forename: Minoru
authors.initials: M
authors.lastname: Ohno
authors.forename: Tetsu
authors.initials: T
authors.lastname: Yamaguchi
authors.forename: Shin-ichi
authors.initials: S
authors.lastname: Momomura
authors.forename: Koji
authors.initials: K
authors.lastname: Narui
mesh_terms: D000842:Ankle / Q000098:blood supply; D002097:C-Reactive Protein / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000209:etiology*; D002320:Cardiovascular Physiological Phenomena; D045422:Continuous Positive Airway Pressure; D003331:Coronary Vessels; D006801:Humans; D006973:Hypertension / Q000209:etiology; D008297:Male; D000683:Serum Amyloid P-Component / Q000378:metabolism*; D020181:Sleep Apnea, Obstructive / Q000150:complications* / Q000628:therapy; D014655:Vascular Resistance; D000099153:Pentraxins
chemical_list: D002097:C-Reactive Protein; D000683:Serum Amyloid P-Component; D000099153:Pentraxins